Screen-detectable cancers account for majority of early-onset cancer cases under age 50

ctDNA predicts early treatment response in HPV-associated anal cancer

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

Strengthening cancer prevention through the Latin American cancer code

DW-MRI reduces futile surgery in colorectal peritoneal metastases undergoing cytoreductive surgery

FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC

Toripalimab plus chemotherapy improves 3-year survival in resectable gastric/GEJ cancer

Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer

Understanding anal cancer risk among people with HIV in sub-Saharan Africa